Literature DB >> 23921425

RNAi gene therapy of SiHa cells via targeting human TERT induces growth inhibition and enhances radiosensitivity.

Wenxuan Zhang1, Lina Xing.   

Abstract

Telomerase activity (TA) is reactivated in more than 90% of all human malignant tumors and normal somatic cells that lack TA. Thus, human TERT (hTERT) is a promising target in malignant tumor treatment. RNA interference is a powerful tool for gene silencing. In this study, we constructed siRNA#1-4 to knock down hTERT. All siRNAs were able to downregulate hTERT differently and we chose siRNA#3 (most effectively) in the following experiments. We studied the effects on cell proliferation, cell cycle, cell apoptosis and radiosensitivity using SiHa cells. Our results showed that siRNA#3 was able to silence hTERT gene effectively. The silencing of hTERT could induce immediate growth arrest, enhance the S phase in cell cycle study and lead to early apoptosis in human cervical cancer cells (SiHa). In clonogenic assays, we used multitarget-single hit and linear-quadratic models to assess the radiosensitivity after knockdown of hTERT. All results of parameters (D0, Dq, α, β) indicated that downregulation of hTERT enhanced radiosensitivity in SiHa cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23921425     DOI: 10.3892/ijo.2013.2051

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  13 in total

1.  MicroRNA-138 inhibits proliferation, migration and invasion through targeting hTERT in cervical cancer.

Authors:  Na Zhou; Dan Fei; Shan Zong; Mingyue Zhang; Ying Yue
Journal:  Oncol Lett       Date:  2016-08-23       Impact factor: 2.967

2.  shRNA-mediated silencing of hTERT suppresses proliferation and promotes apoptosis in osteosarcoma cells.

Authors:  P Chen; W-L Gu; M-Z Gong; J Wang; D-Q Li
Journal:  Cancer Gene Ther       Date:  2017-08-11       Impact factor: 5.987

Review 3.  Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story.

Authors:  Ekati Drakopoulou; Nicholas P Anagnou; Kalliopi I Pappa
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

4.  RNA interference mediated downregulation of human telomerase reverse transcriptase (hTERT) in LN18 cells.

Authors:  Ch Lavanya; M K Sibin; M M Srinivas Bharath; M Jeru Manoj; Manjunatha M Venkataswamy; Dhananjaya I Bhat; K V L Narasinga Rao; G K Chetan
Journal:  Cytotechnology       Date:  2016-10-18       Impact factor: 2.058

5.  Human telomerase reverse transcriptase in papillary thyroid cancer: gene expression, effects of silencing and regulation by BET inhibitors in thyroid cancer cells.

Authors:  Valentina Maggisano; Marilena Celano; Saverio Massimo Lepore; Marialuisa Sponziello; Francesca Rosignolo; Valeria Pecce; Antonella Verrienti; Federica Baldan; Catia Mio; Lorenzo Allegri; Marianna Maranghi; Rosa Falcone; Giuseppe Damante; Diego Russo; Stefania Bulotta
Journal:  Endocrine       Date:  2019-01-19       Impact factor: 3.633

6.  Targeting Human Telomerase Reverse Transcriptase by a Simple siRNA Expression Cassette in HepG2 Cells.

Authors:  Hui Xu; Xia Gong; Hui Hui Zhang; Qin Zhang; Dandan Zhao; Jian Xiong Peng
Journal:  Hepat Mon       Date:  2015-03-31       Impact factor: 0.660

Review 7.  Targeted Gene Delivery Therapies for Cervical Cancer.

Authors:  Ángela Áyen; Yaiza Jiménez Martínez; Houria Boulaiz
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

Review 8.  Effect of therapies-mediated modulation of telomere and/or telomerase on cancer cells radiosensitivity.

Authors:  Ganiou Assani; Yudi Xiong; Fuxiang Zhou; Yunfeng Zhou
Journal:  Oncotarget       Date:  2018-10-09

Review 9.  Telomere Gene Therapy: Polarizing Therapeutic Goals for Treatment of Various Diseases.

Authors:  JinWoo Hong; Chae-Ok Yun
Journal:  Cells       Date:  2019-04-28       Impact factor: 6.600

10.  Silencing of the hTERT gene by shRNA inhibits colon cancer SW480 cell growth in vitro and in vivo.

Authors:  Ai-Qun Liu; Lian-Ying Ge; Xiao-Ling Lu; Xiao-Ling Luo; Yan-Ling Cai; Xing-Qing Ye; Fang-Fang Geng
Journal:  PLoS One       Date:  2014-09-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.